These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1029 related articles for article (PubMed ID: 29964327)

  • 1. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
    Wang M; Ma X; Wang J; Wang L; Wang Y
    Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
    Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma.
    Dai G; Liu G; Zheng D; Song Q
    Eur J Pharmacol; 2021 May; 899():174058. PubMed ID: 33757752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
    Zhao ZL; Zhang L; Huang CF; Ma SR; Bu LL; Liu JF; Yu GT; Liu B; Gutkind JS; Kulkarni AB; Zhang WF; Sun ZJ
    Sci Rep; 2016 Apr; 6():24704. PubMed ID: 27108536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
    Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
    Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.
    Su F; Zhu S; Ruan J; Muftuoglu Y; Zhang L; Yuan Q
    Oncotarget; 2016 Jan; 7(4):4142-54. PubMed ID: 26716652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
    Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
    Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.
    Yu L; Fan Z; Fang S; Yang J; Gao T; Simões BM; Eyre R; Guo W; Clarke RB
    Oncotarget; 2016 May; 7(22):33055-68. PubMed ID: 27102300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
    Bai L; Wang A; Zhang Y; Xu X; Zhang X
    Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
    Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
    Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.
    McAuliffe SM; Morgan SL; Wyant GA; Tran LT; Muto KW; Chen YS; Chin KT; Partridge JC; Poole BB; Cheng KH; Daggett J; Cullen K; Kantoff E; Hasselbatt K; Berkowitz J; Muto MG; Berkowitz RS; Aster JC; Matulonis UA; Dinulescu DM
    Proc Natl Acad Sci U S A; 2012 Oct; 109(43):E2939-48. PubMed ID: 23019585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcoma.
    Pan B; Li Y; Han H; Zhang L; Hu X; Pan Y; Peng Z
    Cancer Sci; 2024 Aug; 115(8):2565-2577. PubMed ID: 38932521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
    Yang Q; Zhang S; Kang M; Dong R; Zhao J
    Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γ-secretase inhibitor DAPT mitigates cisplatin-induced acute kidney injury by suppressing Notch1 signaling.
    Soni H; Matthews AT; Pallikkuth S; Gangaraju R; Adebiyi A
    J Cell Mol Med; 2019 Jan; 23(1):260-270. PubMed ID: 30407728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lethal effects of nanoliposome encapsulated cisplatin on Saos-2 cells and its distribution in nude mice bearing human].
    Wang GW; Guo W; Tang XD; Peng CL; Zhao H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):525-30. PubMed ID: 19829667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
    Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
    Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
    Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
    Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.